Boston Scientific Highlights TAXUS Data at American Heart Association Meeting
(November 5, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that its TAXUS™ Express2™ paclitaxel-eluting coronary stent system will be the subject of 15 presentations at the annual American Heart Association meeting in New Orleans, which opens November 7. These presentations, which include data ranging from 30 days to three years, highlight the depth, consistency and durability of TAXUS data across the TAXUS clinical trials and among increasingly complex cases.

Data will be presented from the TAXUS I, II, IV and VI clinical trials. A major focus will be detailed analysis of Boston Scientific's pivotal TAXUS IV trial data, which is featured in nine presentations, including those on two-year durability, nine-month angiographic follow-up, longer stent lengths, patients with acute coronary syndrome, late loss, renal insufficiency, cost effectiveness and gender-based outcomes.

The TAXUS clinical trials represent the largest body of randomized drug-eluting stent data available today. Together with its "real-world" registries, Boston Scientific has collected data on approximately 11,000 patients. (A registry program enlists clinicians to document the performance of a specific therapy for a particular disease or condition.)

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, intellectual property, litigation and other factors described in the Company's filings with the Securities and Exchange Commission.